125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative

Friday, March 21, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

LEXINGTON, Mass., March 20 As part of its annualsales meeting being held in New Orleans for the first time, IndevusPharmaceuticals (Nasdaq: IDEV), a specialty pharmaceutical company based inLexington, Massachusetts, is dispatching 125 sales representatives to the 1900and 2000 blocks of 6th St. in Central City on March 20 from 9:00-3:30 p.m. tohelp landscape a number of homes for Jericho Road Episcopal HousingInitiative, a faith-based nonprofit organization that provides families andindividuals affordable home ownership opportunities in New Orleans.

"Our mission is to enrich the lives of patients and we can relate toJericho's dedication to improving the lives of Central City residents," saidKurt Lewis, senior vice president of sales & marketing, Indevus. "By havingour annual sales meeting here and partnering with Jericho, we want to inspireother companies to hold their events in New Orleans and to bring their helpinghearts and hands."

Jericho's partner, Crossroads Missions, a nonprofit ministry, will be onsite to manage the project and Cafe Reconcile, a nonprofit group that providestraining and support for at-risk youth to enter the hospitality and restaurantindustries, will serve lunch for the Indevus volunteers at 12:00 p.m.

"What Indevus will accomplish in one day will have a long lasting impacton the lives of Central City residents," said Brad Powers, executive director,Jericho. "We hope that other companies across the country will follow Indevus'lead and lend their time and energy to helping New Orleans families find theAmerican Dream of home ownership."

About Indevus Pharmaceuticals, Inc.

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical companyengaged in the acquisition, development and commercialization of products totreat conditions in urology and endocrinology. The Company's approved productsinclude SANCTURA XR(TM) and SANCTURA(R) for overactive bladder, VANTAS(R) foradvanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, andDELATESTRYL(R) to treat male hypogonadism. The Indevus development pipelinecontains multiple compounds within the Company's core therapeutic areas inaddition to several partnered or partnerable programs. The most advancedcompounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R)for male hypogonadism, PRO 2000 for the prevention of infection by HIV andother sexually-transmitted pathogens, octreotide for acromegaly, and pagoclonefor stuttering.

About the Jericho Road Episcopal Housing Initiative

The Jericho Road Episcopal Housing Initiative creates quality homes forfamilies in the City of New Orleans. Jericho Road was formed in March 2006 andis a partnership of the Episcopal Diocese of Louisiana and Episcopal Reliefand Development (ERD). ERD, the international relief and development agency ofthe Episcopal Church, focuses on three program areas- emergency relief andrebuilding, food security and primary health. ERD is providing technicalsupport to Jericho Road and supplied the initial funding totaling $2.3 millionwhich will be used for administrative management, property acquisition, andconstruction. The funding from ERD combined with planned financing fromvarious community development corporations will result in an investment in theNew Orleans Central City neighborhood of over $20 million.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, thispress release contains forward-looking statements that involve risks anduncertainties that could cause the Company's actual results and financialcondition to differ materially from those anticipated by the forward-lookingstatements. These risks and uncertainties are set forth in the Company'sfilings under the Securities Act of 1933 and the Securities Exchange Act of1934 under "Risk Factors" and elsewhere, and include, but are not limited to:

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store